Nucleus
-
New screening tool amplifies detection of protein changes
A high-throughput method enables researchers to screen hundreds of drugs in parallel, accelerating discovery of therapies that degrade disease-causing proteins.
-
‘Molecular glue’ turns cancer driver into built-in kill switch
Stanford researchers, including Institute Scholar Nathanael Gray and Nucleus Director of Crystallographer Daniel Fernandez, designed a molecule that turns BCL6, a protein that helps drive lymphoma, into a trigger for cancer-cell death.
-
A molecular pearl in an oyster: uncovering the structural basis for potential new cancer drugs
Researchers provide a high-resolution view of new molecular glues that target and kill pancreatic cancer cells
-
Sarafan ChEM-H awards 12 seed grants for new collaborations with the Nucleus
Five $50K awards and seven pilot awards will help researchers at Stanford access high-end instrumentation and expertise within the Nucleus
-
Catching up with last year's winners of the Undergraduate Entrepreneurship Program
Young Stanford biotech entrepreneurs are using their $50,000 award to work towards a cure for a rare muscular dystrophy
-
Undergraduate Entrepreneurship Program celebrates 10th anniversary with annual pitch night
Stanford undergraduates win $50K through a program designed to teach undergraduates about biotech entrepreneurship
-
A new atlas could help guide researchers studying neurological disease
Lab of Institute Scholar Monther Abu-Remaileh has built an atlas of proteins associated with lysosomes in different brain cell types that researchers hope will shed light on neurodegenerative disease.
-
How to crystallize spaghetti
Nucleus collaboration reveals a new protein structure that provides clues towards engineering proteins for sustainable metal capture.
-
Novel cancer-killing mechanism opens path to new treatments
A Stanford-led study found that tegavivint, a drug candidate already in clinical trials, causes a new type of cancer cell death. The findings could inform future use of tegavivint
-
Sarafan ChEM-H awards four $25K seed grants to fund collaborations with the new chemoproteomics group at the Nucleus
The grants will give researchers access to advanced instrumentation and technical guidance for a variety of specialized proteomics techniques.
-
Get to know Olivia Pattelli–Structural Biology Protein Scientist
Our Employee Spotlight Series highlights the amazing individuals working behind the scenes at Sarafan ChEM-H.
-
Researchers find a potential treatment for mitochondrial damage that causes disease
Oxidizing chemicals break this cellular power plant into bits, causing Parkinson’s, ALS, heart disease, diabetes, and cancer—but a molecule could block the process.
-
Sarafan ChEM-H awards six $50,000 grants through inaugural Nucleus Seed Grant Program
The grants will allow Stanford researchers to collaborate with the Nucleus, a collection of labs designed to supercharge basic and translational science at Stanford.
-
ChEM-H celebrates the launch of the Nucleus
The collaborative labs within the Nucleus, led by scientific experts, enable transformative science at Stanford.
-
New strategy could turn IV medicines into pills
Developed by Director of Medicinal Chemistry Mark Smith, the new method could make it possible for chemotherapy patients to take pills rather than receive IV infusions.
-
Going atom-by-atom, Stanford researchers craft a new precision drug for fighting COVID-19
A promising novel drug candidate, designed at the atomic level, could help doctors halt the rise of lethal new drug resistant SARS-CoV-2 variants.
-
A newly published protein structure helps explain how some anti-cancer immunotherapy treatments work
Scientists at Stanford and NYU have published and investigated a new structure of the protein LAG-3 which could enable the development of new cancer treatments.
-
Stanford’s shared facilities make world-class equipment accessible to researchers
Through c-ShARP, Stanford researchers get access to top-notch scientific facilities across campus, including the Nucleus at Sarafan ChEM-H.
-
Driver of neurodegenerative diseases revealed
In searching for how a gene mutation associated with the cell’s recycling center leads to a rare disease, the team identified a missing link in neurodegenerative conditions
-
Study identifies how Epstein-Barr virus triggers multiple sclerosis
A new study found that part of the Epstein-Barr virus mimics a protein made in the brain and spinal cord, leading the immune system to mistakenly attack the body’s nerve cells.
